Kymera Therapeutics, Inc.: 5%+ holders

As of November 9, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Kymera Therapeutics, Inc. The largest reported stake is Fmr LLC's, at 14.3%. 17 filings are on record since July 17, 2025 (Schedule 13G/A, May 6, 2026).

Who owns Kymera Therapeutics, Inc.?

Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies ↓

Sell to companies like Kymera Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-10-27 · Reporting person: BlackRock, Inc. · Sole voting: 5,331,553 · Shared voting: 0 · Sole dispositive: 5,450,286 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
• Filing 2026-09-08 · Reporting person: T. Rowe Price Associates, Inc. · Sole voting: 8,821,580 · Shared voting: 0 · Sole dispositive: 8,873,588 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-09-08
• Filed 2026-08-14 · Holder: T. Rowe Price Associates, Inc. · Percent: 8.6% · SCHEDULE 13G/A
• Filing 2026-08-13 · Reporting person: Atlas Venture Fund X, L.P. · Sole voting: 0 · Shared voting: 2,384,685 · Sole dispositive: 0 · Shared dispositive: 2,384,685 · SCHEDULE 13G/A, 2026-08-13
• Event date 2026-06-26 · Holder: Biotechnology Value Fund L P · Percent: 6.3% · Shares: 2,712,852 · SCHEDULE 13D/A

Kymera Therapeutics, Inc. has 17 Schedule 13D or 13G filings on record since 2025-07-17. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Kymera Therapeutics, Inc. and the warning signs.

See Kymera Therapeutics, Inc.'s free Snapshot Watch Kymera Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Kymera Therapeutics, Inc. and the records around it.

Kymera Therapeutics, Inc. elsewhere on the record

• Leadership changes Jul 2026
• Who owns it

Companies that share a holder

• Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Obsidian Therapeutics, Inc. (Aug 2026), Q32 Bio Inc. (May 2026), GENERATION BIO CO. (May 2026)
• Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
• BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)

Want the whole picture on Kymera Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Kymera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Kymera Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   19 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Kymera Therapeutics, Inc. by CUSIP 501575104 and gives its principal executive office as 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA 02472 (SCHEDULE 13G/A, 2026-10-27).

What the percentages are based on

Fund X Reporting Persons and Opportunity Fund Reporting Persons may be deemed to beneficially own 2.9% and 0.6%, respectively, of the Issuer's outstanding Common Stock, which percentages are calculated based upon 83,150,618 outstanding shares of Common Stock of the Issuer as of July 31, 2026, as reported in the Issuer's 10-Q, filed with the Securities and Exchange Commission on August 5, 2026.Atlas Venture Fund X, L.P., SCHEDULE 13G/A, 2026-08-13

Source of funds (Item 3)

Item 3 is hereby amended and restated to read as follows: The Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 1,960,881 Shares directly beneficially owned by BVF is approximately $54,932,224, including brokerage commissions. The aggregate purchase price of the 751,971 pre-funded warrants (the "Pre-Funded Warrants") owned by BVF is approximately $22,111,156.Biotechnology Value Fund L P, SCHEDULE 13D/A, 2026-06-26

Purpose of Transaction (Item 4)

Baker Bros. Advisors LP

Item 4 of Amendment No. 3 is supplemented and amended, as the case may be, as follows: The disclosure in Item 3 and in Item 6 below is incorporated herein by reference. On December 9, 2025, the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC and Wells Fargo Securities, LLC (the "Underwriters"), related to the public offering (the "Offering") of 7,000,000 shares of common stock of the Issuer ("Common Stock") at a price to the public of $86.00 per share. In addition, the Issuer granted the Underwriters an option exercisable for 30 days from the date of the Underwriting Agreement to purchase, at the public offering price less any underwriting discounts and commissions, up to an additional 1,050,000 shares of Common Stock to cover overallotments, if any ("Underwriters' Option"), which the Underwriters exercised in full on December 10, 2025. The Offering closed on December 11, 2025. Pursuant to the Offering, 667 and Life Sciences purchased 167,192 and 1,838,621 shares of Common Stock, respectively, at the offering price of $86.00 per share, totaling 2,005,813 shares of Common Stock in the aggregate. Each of 667 and Life Sciences purchased the Common Stock with their working capital. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-11; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Kymera Therapeutics, Inc.

Who owns Kymera Therapeutics, Inc.?

On this page, 6 holders' latest ownership filings report 5% or more of Kymera Therapeutics, Inc.: Fmr LLC (14.3%, Schedule 13G/A, filed 2026-05-06), Baker Bros. Advisors LP (10.9%, Schedule 13D/A, filed 2025-12-11), T. Rowe Price Associates, Inc. (10.7%, Schedule 13G/A, filed 2026-09-08), T. Rowe Price Investment Management, Inc. (6.7%, Schedule 13G, filed 2026-05-15) and BlackRock, Inc. (6.6%, Schedule 13G/A, filed 2026-10-27); 1 more is listed above.

Who are the largest shareholders of Kymera Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Kymera Therapeutics, Inc. on this page are Fmr LLC (14.3%), Baker Bros. Advisors LP (10.9%) and T. Rowe Price Associates, Inc. (10.7%).

When did Fmr LLC buy into Kymera Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2025-11-05, reporting 8.2%; its latest, Schedule 13G/A filed 2026-05-06, reports 14.3%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Kymera Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Kymera Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Kymera Therapeutics, Inc. is mentioned again
• Find former Kymera Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes